Cyclic AMP Signaling as a Mediator of Vasculogenic Mimicry in Aggressive Human Melanoma Cells In vitro
Open Access
- 29 January 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (3), 802-809
- https://doi.org/10.1158/0008-5472.can-08-2391
Abstract
Aggressive melanoma cells can engage in a process termed vasculogenic mimicry (VM) that reflects the ability of tumor cells to express a multipotent, stem cell–like phenotype. Melanoma cell plasticity contributes to the lack of efficient therapeutic strategies targeting metastatic tumors. This study reveals cyclic AMP as a mediator of VM in vitro. In uveal and cutaneous metastatic aggressive human melanoma cells, an increase in cyclic AMP by forskolin, dibutyryl cyclic AMP, or G protein–coupled receptor (GPCR) ligands such as adrenaline and vasoactive intestinal peptide inhibited VM to different extents. Although chemical modulators of protein kinase A (PKA) had no effect, a specific pharmacologic activator of Exchange protein directly activated by cyclic AMP (Epac) impaired VM. Ras-associated protein-1 (Rap1) activation assays revealed that cyclic AMP–elevating agents induce a PKA-independent activation of Epac/Rap1. Pharmacologic inhibition of extracellular signal-regulated kinase 1/2 (ERK1/2) activity abolished VM. Phosphorylation of ERK1/2 was PKA-independently inhibited by forskolin but not inhibited by Epac/Rap1 signaling, PKA modulation, or GPCR ligands. Furthermore, the forskolin also inhibited phosphatidyl inositol-3-kinase (PI3K)-mediated activation of protein kinase Akt, as monitored by Ser473 phosphorylation. The pharmacologic activation of Epac and GPCR ligands slightly stimulated Akt, a likely concomitant process of VM modulation. Collectively, these data show that forskolin strongly inhibits VM through PKA-independent activation of Epac/Rap1, PKA-, and Epac-independent inactivation of ERK1/2 and inhibition of PI3K/Akt. The data also show that VM inhibition by GPCR ligands involves mainly the Epac/Rap1-activated signal. Thus cyclic AMP inhibits VM through multiple signaling pathways. [Cancer Res 2009;69(3):802–9]Other Versions
This publication has 37 references indexed in Scilit:
- Interaction between TCL1 and Epac1 in the activation of Akt kinases in plasma membranes and nuclei of 8-CPT-2-O-Me-cAMP-stimulated macrophagesCellular Signalling, 2008
- Vasculogenic mimicry: Current status and future prospectsCancer Letters, 2007
- Molecular Details of cAMP Generation in Mammalian Cells: A Tale of Two SystemsJournal of Molecular Biology, 2006
- Adrenomedullin/Cyclic AMP Pathway Induces Notch Activation and Differentiation of Arterial Endothelial Cells From Vascular ProgenitorsArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Malignant melanoma: genetics and therapeutics in the genomic eraGenes & Development, 2006
- Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressivenessNature Medicine, 2006
- Focal Adhesion Kinase Promotes the Aggressive Melanoma PhenotypeCancer Research, 2005
- Differential Signaling of Cyclic AMPOnline Journal of Public Health Informatics, 2002
- Vascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic MimicryThe American Journal of Pathology, 1999
- Tyrosine 508 of the 85-Kilodalton Subunit of Phosphatidylinositol 3-Kinase Is Phosphorylated by the Platelet-Derived Growth Factor ReceptorBiochemistry, 1994